tiprankstipranks
Trending News
More News >
Capstone Therapeutics Corp (CAPS)
NASDAQ:CAPS
US Market
Advertisement

Capstone Therapeutics (CAPS) AI Stock Analysis

Compare
49 Followers

Top Page

CAPS

Capstone Therapeutics

(NASDAQ:CAPS)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$0.91
▼(-4.63% Downside)
Capstone Therapeutics' overall stock score is primarily impacted by its weak financial performance and valuation, reflecting significant risks. However, recent corporate events provide a positive outlook, potentially improving future revenue and financial stability. Technical analysis shows a bearish trend, but not excessively so, contributing to a moderate overall score.
Positive Factors
Strategic Acquisitions
The acquisition of Canadian Stone Industries expands Capstone's North American footprint and strengthens its brand portfolio, enhancing market position and accelerating revenue growth.
Industry Demand Trends
Long-term industry trends in remodeling and outdoor projects align with Capstone's strengths, positioning the company to capture significant market share and drive sustained growth.
Operational Integration
Efficient integration of acquisitions into Capstone's systems enhances operational efficiency, cost synergies, and margin expansion, supporting long-term profitability.
Negative Factors
Declining Revenue
Consistent revenue decline indicates challenges in market competitiveness and product adoption, potentially impacting long-term growth prospects and financial stability.
Negative Equity
Negative equity reflects financial instability, limiting the company's ability to secure financing and invest in growth opportunities, posing long-term financial risks.
Shrinking Profit Margins
Decreasing profit margins indicate rising costs or pricing pressures, which can erode profitability and hinder the company's ability to reinvest in business growth.

Capstone Therapeutics (CAPS) vs. SPDR S&P 500 ETF (SPY)

Capstone Therapeutics Business Overview & Revenue Model

Company DescriptionCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
How the Company Makes MoneyCapstone Therapeutics generates revenue through multiple streams, primarily from the development and commercialization of its therapeutic products. The company may receive funding from strategic partnerships with larger pharmaceutical companies, including milestone payments and royalties based on product sales once they reach the market. Additional revenue may come from government grants or research contracts that support the development of its therapies. Moreover, licensing agreements for its proprietary technologies can also contribute to its earnings, offering Capstone a diversified revenue model that leverages both product sales and collaborative research efforts.

Capstone Therapeutics Financial Statement Overview

Summary
Capstone Therapeutics faces significant financial challenges, with declining revenue and profitability, alongside negative equity and high leverage, posing substantial risks. While cash flow management shows improvement, the company must address its structural financial weaknesses to restore stability and growth potential.
Income Statement
45
Neutral
Capstone Therapeutics has experienced declining revenue over the past few years, dropping from $61.56M in 2022 to $44.88M in 2024. Gross profit margin decreased from 26.9% in 2022 to 21.3% in 2024, indicating shrinking profitability. The company has posted net losses over the last two years, with a net loss margin of -12.2% in 2024, reflecting ongoing challenges in achieving profitability.
Balance Sheet
30
Negative
The company's balance sheet shows negative stockholders' equity of -$3.06M in 2024, a concerning sign of financial instability and potential risk. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, further indicating financial distress. These factors suggest significant leverage and financial risk.
Cash Flow
55
Neutral
Capstone has shown improvement in free cash flow from $1.24M in 2023 to $3.70M in 2024, showcasing strong free cash flow growth. The operating cash flow to net income ratio is favorable, though the company continues to face net losses. This implies effective cash management but highlights the need for sustained profitability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue44.72M44.88M48.35M61.56M66.74M45.45M
Gross Profit9.78M9.57M9.61M16.53M16.32M10.94M
EBITDA-2.86M-121.00K-1.75M4.23M5.02M2.64M
Net Income-5.54M-2.56M-3.82M2.31M3.92M10.46M
Balance Sheet
Total Assets58.48M47.22M52.70M65.21M60.85M54.87M
Cash, Cash Equivalents and Short-Term Investments730.00K11.00K52.00K23.00K50.00K0.00
Total Debt23.25M16.61M20.33M28.80M28.34M20.81M
Total Liabilities31.33M50.28M50.26M57.04M31.78M25.77M
Stockholders Equity27.16M-3.06M2.44M8.17M29.08M29.11M
Cash Flow
Free Cash Flow-1.17M3.70M1.24M-3.06M2.55M639.00K
Operating Cash Flow-1.15M3.82M1.45M-2.89M3.72M642.00K
Investing Cash Flow-2.46M-120.00K-208.00K-173.00K-931.00K-3.00K
Financing Cash Flow4.32M-3.74M-1.21M3.04M-2.74M-697.00K

Capstone Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.95
Price Trends
50DMA
1.04
Negative
100DMA
1.19
Negative
200DMA
1.67
Negative
Market Momentum
MACD
-0.04
Negative
RSI
51.30
Neutral
STOCH
86.66
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPS, the sentiment is Neutral. The current price of 0.95 is above the 20-day moving average (MA) of 0.90, below the 50-day MA of 1.04, and below the 200-day MA of 1.67, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 51.30 is Neutral, neither overbought nor oversold. The STOCH value of 86.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CAPS.

Capstone Therapeutics Risk Analysis

Capstone Therapeutics disclosed 18 risk factors in its most recent earnings report. Capstone Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Capstone Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
49
Neutral
$7.64M-0.07-20.23%1.52%77.22%
41
Neutral
$7.74M-0.22
35
Underperform
$89.55M-0.37-94.35%80.73%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CAPS
Capstone Therapeutics
0.95
-2.13
-69.16%
RETO
ReTo Eco-Solutions
3.25
-48.75
-93.75%
FEAM
5E Advanced Materials, Inc.
4.14
-6.21
-60.00%
STAI
ScanTech AI Systems
0.29
-10.58
-97.38%

Capstone Therapeutics Corporate Events

M&A TransactionsBusiness Operations and Strategy
Capstone Completes Acquisition of Canadian Stone Industries
Positive
Dec 2, 2025

On December 1, 2025, Capstone Holding Corp. completed the acquisition of Canadian Stone Industries, a distributor with $15 million in annual revenue, which expands Capstone’s North American footprint and strengthens its brand portfolio. This acquisition is expected to immediately increase revenue and EBITDA, advancing Capstone towards its $100 million revenue target for early 2026, and reflects the company’s strategy of acquiring high-quality businesses to enhance its market position.

Private Placements and FinancingBusiness Operations and Strategy
Capstone Therapeutics Adjusts Convertible Note Conversion Price
Neutral
Nov 28, 2025

Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes with an original principal amount of up to $10,909,885. On November 28, 2025, the company and the buyer agreed to reduce the conversion price of the July 2025 Convertible Note to $0.75 for the remaining principal amount of $500,744.01, and for $1,772,856.21 of the October 2025 Convertible Note, potentially impacting the company’s stock conversion strategy.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Capstone Therapeutics Approves Reincorporation to Nevada
Neutral
Nov 24, 2025

On November 18, 2025, Capstone Holding Corp. held its annual stockholders meeting where several key proposals were voted upon. The meeting, which had a quorum with 74.78% of votes represented, resulted in the election of two directors, the ratification of GBQ Partners LLC as the independent auditor, and the approval of the company’s reincorporation from Delaware to Nevada. Additionally, the 2025 Stock Incentive Plan was adopted, and executive compensation was approved to be reviewed every three years. These decisions are likely to impact the company’s governance and operational structure moving forward.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Capstone Therapeutics Reports Record Q3 2025 Financial Results
Positive
Nov 17, 2025

Capstone Holding Corp. reported record financial results for the third quarter of 2025, with a 19% year-over-year increase in pro forma revenue and a 46% rise in adjusted EBITDA. The company announced two acquisitions expected to contribute $26 million in annualized revenue, accelerating its path toward a $100 million run-rate by early 2026. The improved economic conditions and a favorable industry outlook, supported by interest rate cuts and a recovery in demand, provide strong long-term growth prospects for Capstone. The company has also achieved integration milestones with its recent acquisition, positioning itself for rapid post-close integration of future acquisitions.

M&A TransactionsBusiness Operations and Strategy
Capstone Completes Acquisition of Carolina Stone Holdings
Positive
Nov 7, 2025

On August 22, 2025, Capstone Holding Corp. completed its acquisition of Carolina Stone Holdings, LLC, and its subsidiary, Carolina Stone Distributors, LLC, from D22L, Inc. and other sellers. The transaction involved a cash payment of $2,625,000, subject to adjustments, and a seller note of $1,250,000. This acquisition is expected to enhance Capstone’s market presence in the stone products industry by expanding its operational capabilities and market reach.

Private Placements and FinancingRegulatory Filings and Compliance
Capstone Therapeutics Issues Second Convertible Note
Neutral
Oct 23, 2025

Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes. On October 22, 2025, Capstone issued a second convertible note worth $3,545,712.42, convertible into common stock at a price of $1.10 per share. The company received gross proceeds of $3,250,000 from this issuance and plans to file a registration statement with the SEC for the resale of the stock. Joseph Gunnar & Co., LLC acted as the sales agent for this financing.

Private Placements and FinancingBusiness Operations and Strategy
Capstone Therapeutics Strengthens Balance Sheet with Debt Exchange
Positive
Oct 6, 2025

On September 30, 2025, Capstone Holding Corp. entered into an Exchange Agreement with Brookstone entities to exchange $1.9 million in debt for newly issued non-convertible preferred equity, Series Z Preferred shares. This strategic move, approved by the Board, strengthens Capstone’s balance sheet by eliminating targeted debt and reducing interest expenses by over $170,000, without diluting common shareholders. The transaction enhances Capstone’s financial flexibility, positioning the company for potential accretive acquisitions and signaling confidence in its long-term cash flows.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025